Mezquita, B., Reyes-Farias, M., & Pons, M. (2024). FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.
Citación estilo ChicagoMezquita, Betlem, Marjorie Reyes-Farias, y Miquel Pons. FDA-approved Antivirals Ledipasvir and Daclatasvir Downregulate the Src-EPHA2-Akt Oncogenic Pathway in Colorectal and Triple-negative Breast Cancer Cells. 2024.
Cita MLAMezquita, Betlem, Marjorie Reyes-Farias, y Miquel Pons. FDA-approved Antivirals Ledipasvir and Daclatasvir Downregulate the Src-EPHA2-Akt Oncogenic Pathway in Colorectal and Triple-negative Breast Cancer Cells. 2024.
Precaución: Estas citas no son 100% exactas.